PRESS-RELEASE filed Mar 18, 2026 at 08:00 ET
Lifeward reported declining revenue and earnings for Q4 and full-year 2025, with Q4 revenue down 33% YoY to $5.1M and adjusted net loss widening. However, the company secured shareholder approval for a transformative strategic transaction with Oramed, gaining access to oral protein delivery technology and up to $47M in funding, which positions it for a potential turnaround. The deal, combined with cost reductions and strategic acquisitions, aims to drive future growth and achieve cash flow positivity.